Comparisons of efficacy and safety between docetaxel + cisplatin and paclitaxel + cisplatin and their effects on serum HE4, CA125 and ROMA indicators in patients with ovarian carcinoma.
To explore the efficacy and safety of docetaxel (DTX) + cisplatin (DDP) and paclitaxel (TAX) + DDP and their effects on serum human epididymis protein 4 (HE4), carbohydrate antigen 125 (CA125) and risk of ovarian malignancy algorithm (ROMA) index in the treatment of ovarian carcinoma. A total of 90 patients admitted and treated in our hospital from February 2017 to June 2018, with definitely diagnosed ovarian carcinoma via pathological biopsy were selected. The included patients were randomly divided into two groups: DTX+DDP group (n=45) and TAX+DDP group (n=45). With 3 weeks as a course, the treatments lasted for 6 consecutive courses. The changes in serum vascular endothelial growth factor (VEGF), matrix metalloproteinase 2 (MMP-2), HE4, CA125 and ROMA index were detected before and after treatments. Moreover, the incidence of adverse reactions was observed, and the clinical therapeutic efficacy was assessed. The clinical efficacy in both groups revealed that there were 39 and 34 cases obtained complete remission or partial remission in the DTX+DDP group and in the TAX+DDP group, respectively. Overall efficiencies were 86.67 and 75.56%, respectively, showing statistically significant differences between the two groups (p<0.05). The incidence rate of adverse reactions in DTX+DDP group was significantly lower than that in TAX+DDP group (p<0.05). The VEGF and MMP-2 levels in both DTX+DDP and TAX+DDP group were decreased compared with those before treatment (183.35±25.26 vs. 279.18±27.75 pg/mL and 228.22±40.21 vs. 316.11±33.6 pg/mL (p<0.05). The serum HE4 and CA125 levels and ROMA index in both groups were lower than those before treatment (121.19±14.14 vs. 159.43±18.15 pmol/L) (p<0.05), 239.45±25.37 vs. 288.37±30.36 pmol/L (p<0.05) and 58.02±6.61 vs. 76.23±11.58 (p<0.05), respectively). The above indicators were decreased in the DTX+DDP group to a significant extent (p<0.05). Both DTX+DDP and TAX+DDP treatments are effective for the patients with ovarian carcinoma. However, DTX+DDP is more efficacious in lowering indicators such as serum CA125, HE4 and MMP-2 and ROMA index and adverse reactions, thus providing a more efficient practice scheme with lower toxic side effects for the clinical treatment of ovarian carcinoma.